by Backoffice | Nov 30, 2022 | Trial results
The Danish Medicines Agency has November 23rd, 2022, approved the un-blinded phase I dose-titrating clinical trial where children with autism and signs of leaky gut syndrome are treated with allogeneic adipose-derived mesenchymal stem cells (ASCs). The children will...
by Backoffice | Apr 29, 2022 | Trial results
The objective of the phase I clinical trial was to evaluate safety and provide proof of concept for efficacy of allogeneic adipose tissue-derived mesenchymal stromal cells (ASCs) injected into the major salivary glands in cancer patients with salivary glands damaged...
by Backoffice | Jan 14, 2020 | Trial results
The clinical phase I study evaluated the safety and feasibility of injecting allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland as a treatment of aqueous deficient dry eye disease (ADDE) Sjögrens syndrome. The study found injection of...
